Loading...

SPARC Sun Pharma Advanced Research Company Ltd Legal Disputes Announcement

Sn P

SPRC

Sun Pharma Advanced Research Company Ltd

(SPARC)

2025 Announcement

Regulatory clarification

Civil Litigation

R&D Consolidation

Regulation 47 Disclosure

Unaudited results

Unaudited results

Volume Clarification

Compliance Confirmation

Financial Results Published

Newspaper Announcement

Annual General Meeting

Compliance Certificate

AGM Announcement

New Subsidiary Created

Vibozilimod Update

Price Movement Clarification

Annual Compliance Report

Financial Results

New Auditor Appointment

Director Appointments

Compliance Certificate

IND Application Submitted

Price Movement Clarification

Credit Rating Downgrade

Financial Results Update

Management Change

Compliance Certificate

Investor Call Update

Investor Presentation

New Oncology Asset

Investor Presentation

Volume Increase Clarification

Financial Results

Financial Results Correction

Dematerialization Confirmation

Management Change

Financial Results Publication

Management Change

Change in Management

Newspaper Advertisement

Director Appointment

Newspaper Publication

Confirmation Certificate

Advertisement and Financial...

Management Change

Personnel Changes

Deviation in the use of pro...

Funds raising and CFO changes

Financial Results Approval ...

Compliance Report

Investor Call Outcome

Compliance Confirmation

Compliance Certificate

Results Announcement

Financial Results Published

Preferential Issue Proceeds

Investor Conference

Confirmation Certificate Su...

Investor Presentation

Investor Presentation

Conference Presentation

Meeting Schedule

Clarification on Price Move...

Investor Call on Vodobatini...

Investor Call Transcript

Deviation in Use of Proceeds

Management Change

Update on Clinical Programs...

License Agreement for SCD -...

Enrollment Completed in Pha...

Compliance Confirmation

Update on Clinical Programs...

Confirmation Certificate

Incorporation of Wholly Own...

Appointment of Company Secr...

Resignation of Company Secr...

Civil Litigations

Financial Statements

Strategic Focus on Specific...

No deviation or variation i...

Financial Statements

Regulatory Compliance

Financial Statements

Financial Statements

Financial Results Publication

Divestment of Assets

Rights Offerings

Equity, Debt, VC, Private E...

External Links:

Data:

SPARC reports FDA CRL resubmission for PDP-716 NDA by Ocuvex; primary issues relate to third-party API facility inspections, with no new efficacy or safety concerns raised. Awaiting FDA determination on completeness of the resubmission.

AI Assistant

Sun Pharma Advanced Research Company Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.